Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors
一项旨在确定自体外周血单核细胞经修饰可呈递 HPV16 抗原 (SQZ-PBMC-HPV) 在 HLA-A*02+ HPV16+ 实体瘤患者中的安全性和剂量的 1 期研究
期刊:Investigational New Drugs
影响因子:2.7
doi:10.1007/s10637-023-01342-x
Jimeno, Antonio; Baranda, Joaquina; Iams, Wade T; Park, Jong Chul; Mita, Monica; Gordon, Michael S; Taylor, Matthew; Dhani, Neesha; Leal, Alexis D; Neupane, Prakash; Eng, Cathy; Yeku, Oladapo; Mita, Alain; Moser, Justin C; Butler, Marcus; Loughhead, Scott M; Jennings, Julia; Miselis, Nathan R; Ji, Rui-Ru; Nair, Nitya; Kornacker, Martin; Zwirtes, Ricardo F; Bernstein, Howard; Sharei, Armon
